Government Pharma Investigations Target Pricing, Opioids, Trade Practices
While DOJ probes have declined in last few years, 13 of top 25 pharma companies are dealing with ongoing inquiries of marketing and pricing practices.
You may also be interested in...
Two settlements totaling $729m resolve kickback claims related to speaker programs and copay charities; Novartis will limit payments to healthcare professionals for providing medical education under a new corporate integrity agreement.
Government is pursuing behavior it once would have taken a pass on, former DOJ attorney notes; pharma companies have inked 16 settlements in past year.
$1.4b payment to settle investigation of marketing of opioid addition treatment is biggest for a pharma in several years.